SCHEMBL15550871

SCHEMBL15550871

O=C1NCC(F)C1F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30497322 0.74
SCHEMBL19077992 0.74
SCHEMBL3921356 0.74
SCHEMBL30497360 0.74
SCHEMBL30497292 0.74
SCHEMBL31268347 0.74
SCHEMBL30497349 0.74
SCHEMBL29620173 0.74
SCHEMBL30497369 0.74
SCHEMBL30497379 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107802623-B Difluorolactam compositions for EP 4-mediated bone-related diseases and disorders 开曼化学股份有限公司 2020-10-30 CN disclosed
CN-106748951-B Difluorolactam compounds as EP4 receptor selective agonists for use in the treatment of EP4 mediated diseases and conditions 开曼化学股份有限公司 2020-07-24 CN disclosed
EP-3021879-A2 METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH Cayman Chemical Company, Incorporated (US) 2016-05-25 EP disclosed
EP-2875022-A1 DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS Cayman Chemical Company, Incorporated (US) 2015-05-27 EP disclosed
EP-2874620-A1 DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS Cayman Chemical Company, Incorporated (US) 2015-05-27 EP disclosed
WO-2015009991-A2 METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH CAYMAN CHEMICAL COMPANY, INC. (US) 2015-01-22 WO disclosed
WO-2014015247-A1 DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS CAYMAN CHEMICAL COMPANY, INC. (US) 2014-01-23 WO disclosed
WO-2014015246-A1 DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS CAYMAN CHEMICAL COMPANY, INC. (US) 2014-01-23 WO disclosed